Bullish & Foolish
Full BOLT fundamentals All 466 on the Survival Watch

BOLTBolt Biotherapeutics, Inc.

Is Bolt Biotherapeutics struggling financially?

Yes, by its own account. Bolt Biotherapeutics told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

  • Restructuring

    We incurred a restructuring charge of $1.5 million in one-time termination benefits, such as severance costs and related benefits.

    Form 10-Q, filed 12 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$7.1M
Source filing
10-Q 12 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 2months

    If the burn speeds up

    Empty by Aug 2026

  • 4months

    If it eases off

    Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$17.6M

÷

Cash burned over the last 12 months

$62.5M

What Bolt Biotherapeutics told the SEC

…its cash and cash equivalents and marketable securities of $ 23.9 million as of March 31, 2026 will not be sufficient for the Company to continue as a going concern for at least one year from the issuance date of these financial statements. The Company believes that this raises substantial doubt about its ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements. As a result, the Company will be…

Bolt Biotherapeutics, Inc., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 36% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt